Guadalupe Cabral wins Pfizer2019-Clinical Research Award

Guadalupe Cabral, researcher from the Tissue Repair and Inflammation Lab led by António Jacinto won the Pfizer2019 - Clinical Research Award for her work in the area of breast cancer, one of the leading causes of cancer death in young women.

Guadalupe Cabral, Diana Saraiva, António Jacinto | Guadalupe Cabral

The work of Guadalupe Cabral distinguished with this award, published in the journal Frontiers in Immunology in late 2018, identified a predictive marker of response to Neoadjuvant Chemotherapy in women with breast cancer.

Full article: Saraiva DP, Jacinto A, Borralho P, Braga S, Cabral MG (2018) HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy Front. Immunol. 9:2605. doi: 10.3389/fimmu.2018.02605

This work resulted from a collaboration between CEDOC-NMS|FCM with the CUF Institute of Oncology under TagusTANK, a consortium of José de Mello Saúde/CUF with the NOVA University of Lisbon.

Simultaneously, João Peça, from Centro de Neurociências e Biologia Celular and Departamento de Ciências da Vida, FCT, Universidade de Coimbra, won Pfizer2019 - Basic Research Award for his work dedicated to autism area.

The Award Ceremony will take place on November 14, 2019, at Teatro Thalia, with the presence of Luís Graça - President of the Lisbon Society of Medical Sciences, and Paulo Teixeira - Managing Director of Pfizer Portugal.

More information on the Press Releas (portuguese).

Written by